Nivolumab + Cabozantinib (N+C) vs Sunitinib (S) en première ligne (1L) de traitement chez des patients atteints d’un carcinome rénal avancé (ACCR) dans l’essai de phase III checkmate 9ER : analyse en sous-groupes basée sur l’absence ou présence de néphrectomie antérieure
Year: 2021
Type: article
Source: The French Journal of Urology
Authors: B. Escudier, C. Porta, M. Burotto, C. Suarez, M. Bourlon, J. Hsieh, A. Shah, A. Hamzaj, J. Bedke, D. Pook, E. Kessler, Y. Tomita, A. Drakaki, J. Zhang, B. Simsek, G. Schwab, R. Motzer, T. Choueiri, A. Apolo, T. Powles
Institutions: Institut Gustave Roussy, Fondation Gustave Roussy, University of Pavia, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Washington University in St. Louis, The University of Texas MD Anderson Cancer Center, Ospedale San Donato, University of Tübingen, Cabrini Hospital, Monash University, University of Colorado Anschutz, Niigata University, University of California, Los Angeles, Bristol-Myers Squibb (United States), Exelixis (United States), Memorial Sloan Kettering Cancer Center, Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, National Institutes of Health, National Cancer Institute, Center for Cancer Research, National Health Service, Queen Mary University of London, The Royal Free Hospital, Cancer Research UK, Barts Cancer Institute
Language: French
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3209706938